[
  {
    "ts": null,
    "headline": "AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth",
    "summary": "ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.",
    "url": "https://finnhub.io/api/news?id=70f3dd6c2b69b2c91a5bf2faf1f22e846bf3388610f0401f0532df8a98bdeb6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755869940,
      "headline": "AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth",
      "id": 136478895,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.",
      "url": "https://finnhub.io/api/news?id=70f3dd6c2b69b2c91a5bf2faf1f22e846bf3388610f0401f0532df8a98bdeb6d"
    }
  },
  {
    "ts": null,
    "headline": "ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth",
    "summary": "AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.",
    "url": "https://finnhub.io/api/news?id=a7b2ccc1f9ade8de00401e0212298710d33b7bd95149a5b22a9b9be9139c8f8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755866580,
      "headline": "ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth",
      "id": 136476664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.",
      "url": "https://finnhub.io/api/news?id=a7b2ccc1f9ade8de00401e0212298710d33b7bd95149a5b22a9b9be9139c8f8d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie seeks Rinvoq alopecia approval after second Phase III success",
    "summary": "If approved, Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than competitor Olumiant.",
    "url": "https://finnhub.io/api/news?id=6cc1347f97b0a56f331667be5de97998e131dd83dfddeee9a68fe72b2f2ad7c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755862224,
      "headline": "AbbVie seeks Rinvoq alopecia approval after second Phase III success",
      "id": 136476665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "If approved, Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than competitor Olumiant.",
      "url": "https://finnhub.io/api/news?id=6cc1347f97b0a56f331667be5de97998e131dd83dfddeee9a68fe72b2f2ad7c1"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: Strong Dividend Grower Made Even Better With Writing Options",
    "summary": "Read how we use the option wheel on SCHD for providing more consistent 'income' every month, along with our core long position that sits back and collects the dividend passively.",
    "url": "https://finnhub.io/api/news?id=0155f08f5cd2ddac3b63606ae8deb8e0912b31455397ba1d18b05a76c24db8ef",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755861875,
      "headline": "SCHD: Strong Dividend Grower Made Even Better With Writing Options",
      "id": 136477090,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1301983584/image_1301983584.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Read how we use the option wheel on SCHD for providing more consistent 'income' every month, along with our core long position that sits back and collects the dividend passively.",
      "url": "https://finnhub.io/api/news?id=0155f08f5cd2ddac3b63606ae8deb8e0912b31455397ba1d18b05a76c24db8ef"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Alphabet, Exxon Mobil and AbbVie",
    "summary": "Alphabet, Exxon Mobil, and AbbVie remain Zacks' top coverage picks as each navigates industry shifts while driving long-term growth.",
    "url": "https://finnhub.io/api/news?id=d9389faf769e08f6214c44929a84fb693a2ec17e8e4abcf9c36877ef0bfade24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755855960,
      "headline": "The Zacks Analyst Blog Highlights Alphabet, Exxon Mobil and AbbVie",
      "id": 136476615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Alphabet, Exxon Mobil, and AbbVie remain Zacks' top coverage picks as each navigates industry shifts while driving long-term growth.",
      "url": "https://finnhub.io/api/news?id=d9389faf769e08f6214c44929a84fb693a2ec17e8e4abcf9c36877ef0bfade24"
    }
  }
]